Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression. Current guidelines recommend that patients with stage T1 NMIBC undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery to remove residual tumor, confirm staging, and obtain additional pathological information. However, the benefits of routine re-TURBT for all high-risk patients remain controversial, as many patients may not have residual disease, while the procedure carries surgical and anesthetic risks, physical and psychological burden, and additional healthcare costs. Urine tumor DNA (utDNA) refers to DNA fragments shed by tumor cells into urine. It can be detected using molecular assays with high sensitivity and specificity, offering a non-invasive method for bladder cancer diagnosis and surveillance. Previous studies have shown that positive utDNA results after initial TURBT may be associated with residual disease and higher recurrence risk. This multicenter, randomized controlled trial aims to evaluate whether utDNA testing can accurately identify NMIBC patients who are most likely to benefit from re-TURBT, thereby guiding the decision to perform the procedure. The goal is to optimize patient selection for re-TURBT, reduce unnecessary surgeries, and improve patient quality of life while maintaining oncologic safety.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony histologicznie rak pęcherza, który nie rozprzestrzenia się na głębokie warstwy ani na inne organy
- •Rak pęcherza typu urothelial carcinoma lub zawierający go jako główny składnik (ponad 50%)
- •Co najmniej jeden z warunków: niekompletna pierwsza operacja, brak mięśni w próbce z pierwszej operacji, lub guz w stadium T1
- •Gotowość do pobrania próbki moczu między 2-6 tygodniami po pierwszej operacji
- •Gotowość do oddania próbki tkanki guza do badania
- •Gotowość do badań genetycznych wymaganych w badaniu
✗ Disqualifies
- •Przeciwwskazania medyczne do operacji TURBT
- •Jednoczesny rak górnych dróg moczowych (moczowodu lub nerki)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Nanchang Second People's Hospital
Nanchang, China
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, China
Xingtai People's Hospital
Xingtai, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, China
Renji Hospital
Shanghai, China
The Second Hospital of Tianjin Medical University
Tianjin, China
General Hospital of Tianjin Medical University
Tianjin, China
Trial contact
Hailong Hu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.